{
    "id": 26513,
    "fullName": "CCNE1 mutant",
    "impact": "unknown",
    "proteinEffect": "unknown",
    "geneVariantDescriptions": [
        {
            "description": "CCNE1 mutant indicates an unspecified mutation in the CCNE1 gene.",
            "references": [
                {
                    "id": 275,
                    "pubMedId": null,
                    "title": "External Reference Not Available (N/A)",
                    "url": "https://ckb.jax.org/about/glossaryOfTerms"
                }
            ]
        }
    ],
    "type": "category",
    "gene": {
        "id": 898,
        "geneSymbol": "CCNE1",
        "terms": [
            "CCNE1",
            "CCNE",
            "pCCNE1"
        ]
    },
    "variant": "mutant",
    "createDate": "05/03/2017",
    "updateDate": "12/11/2018",
    "referenceTranscriptCoordinates": null,
    "partnerGenes": [
        
    ],
    "evidence": [
        {
            "id": 11780,
            "approvalStatus": "Phase II",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a Phase II trial, Paraplatin (carboplatin) and Adavosertib (MK-1775) combination treatment resulted in partial response in an ovarian cancer patient harboring TP53 H193Y and mutations in CCNE1 (PMID: 27998224).",
            "molecularProfile": {
                "id": 28236,
                "profileName": "CCNE1 mut TP53 H193Y"
            },
            "therapy": {
                "id": 1194,
                "therapyName": "Adavosertib + Carboplatin",
                "synonyms": null
            },
            "indication": {
                "id": 2394,
                "name": "ovarian cancer",
                "source": "DOID"
            },
            "responseType": "predicted - sensitive",
            "references": [
                {
                    "id": 9762,
                    "pubMedId": 27998224,
                    "title": "Phase II Study of WEE1 Inhibitor AZD1775 Plus Carboplatin in Patients With TP53-Mutated Ovarian Cancer Refractory or Resistant to First-Line Therapy Within 3 Months.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/27998224"
                }
            ],
            "ampCapAscoEvidenceLevel": "B",
            "ampCapAscoInferredTier": "I"
        },
        {
            "id": 11777,
            "approvalStatus": "Phase II",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a Phase II trial, Paraplatin (carboplatin) and Adavosertib (MK-1775) combination treatment resulted in partial response in an ovarian cancer patient harboring TP53 L114fs and mutations in CCNE1 (PMID: 27998224).",
            "molecularProfile": {
                "id": 28238,
                "profileName": "CCNE1 mut TP53 L114fs"
            },
            "therapy": {
                "id": 1194,
                "therapyName": "Adavosertib + Carboplatin",
                "synonyms": null
            },
            "indication": {
                "id": 2394,
                "name": "ovarian cancer",
                "source": "DOID"
            },
            "responseType": "predicted - sensitive",
            "references": [
                {
                    "id": 9762,
                    "pubMedId": 27998224,
                    "title": "Phase II Study of WEE1 Inhibitor AZD1775 Plus Carboplatin in Patients With TP53-Mutated Ovarian Cancer Refractory or Resistant to First-Line Therapy Within 3 Months.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/27998224"
                }
            ],
            "ampCapAscoEvidenceLevel": "B",
            "ampCapAscoInferredTier": "I"
        },
        {
            "id": 11776,
            "approvalStatus": "Phase II",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a Phase II trial, Paraplatin (carboplatin) and Adavosertib (MK-1775) combination treatment resulted in complete response in an ovarian cancer patient harboring a TP53 exon 7 mutation, and mutations in BRCA1, CCNE1, and MYC (PMID: 27998224).",
            "molecularProfile": {
                "id": 28239,
                "profileName": "BRCA1 mut CCNE1 mut MYC mut TP53 exon7"
            },
            "therapy": {
                "id": 1194,
                "therapyName": "Adavosertib + Carboplatin",
                "synonyms": null
            },
            "indication": {
                "id": 2394,
                "name": "ovarian cancer",
                "source": "DOID"
            },
            "responseType": "predicted - sensitive",
            "references": [
                {
                    "id": 9762,
                    "pubMedId": 27998224,
                    "title": "Phase II Study of WEE1 Inhibitor AZD1775 Plus Carboplatin in Patients With TP53-Mutated Ovarian Cancer Refractory or Resistant to First-Line Therapy Within 3 Months.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/27998224"
                }
            ],
            "ampCapAscoEvidenceLevel": "B",
            "ampCapAscoInferredTier": "I"
        }
    ],
    "molecularProfiles": [
        {
            "id": 27752,
            "profileName": "CCNE1 mutant",
            "profileTreatmentApproaches": [
                
            ]
        },
        {
            "id": 28236,
            "profileName": "CCNE1 mut TP53 H193Y",
            "profileTreatmentApproaches": [
                
            ]
        },
        {
            "id": 28238,
            "profileName": "CCNE1 mut TP53 L114fs",
            "profileTreatmentApproaches": [
                
            ]
        },
        {
            "id": 28239,
            "profileName": "BRCA1 mut CCNE1 mut MYC mut TP53 exon7",
            "profileTreatmentApproaches": [
                
            ]
        }
    ],
    "allTranscriptCoordinates": [
        
    ]
}